The UK’s health watchdog has issued a new warning about semaglutide, a popular treatment for type 2 diabetes and weight loss. Semaglutide is used to help lower appetite and boost insulin levels. It’s sold under names like Rybelsus, Ozempic, and Wegovy.
Recent updates reveal a very rare side effect called non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to sudden vision loss. This eye condition occurs when blood flow to the optic nerve decreases. Experts have linked this side effect to semaglutide usage, although only three cases have been reported in the UK since the drug was approved in 2018.
Dr. Alison Cave, Chief Safety Officer at the Medicines and Healthcare products Regulatory Agency (MHRA), emphasized the importance of monitoring these developments. “While the potential risk of NAION is extremely small, patients and healthcare professionals should be aware of the symptoms,” she stated. Symptoms include sudden changes in vision, which require immediate medical attention.
Novo Nordisk, the company behind these medications, reassures patients that safety is their main priority. They confirm that the official guidelines have been updated to include information about NAION, although they maintain that the evidence doesn’t strongly link the drug to the condition.
Interestingly, a recent survey showed that nearly 70% of people using semaglutide felt that the benefits outweighed their concerns, highlighting the importance of ongoing patient education and awareness.
In comparison, a similar weight-loss medication in the past faced backlash for misleading claims, which underscores the need for transparency in drug safety. As users discuss their experiences on social media, a trend emerges showing that many are willing to accept some risks for the chance at significant weight loss.
For anyone considering semaglutide treatments, staying informed and monitoring any changes in health is crucial. Learn more about the MHRA’s guidance here.
Source link
Weight loss, Drugs, Health
